Cencora's Ameer Ali explains why trading partners' systems, not the NDC-12 deadline itself, determine whether product keeps moving through the supply chain during the transition.
|Videos|June 27, 2023
DIA 2023: Cal Collins Discusses SMART on FHIR and Supply Chains
In an interview at the DIA Global Annual Meeting with Pharma Commerce Editor, Nicholas Saraceno, Cal Collins, CEO of OpenClinica discusses SMART on FHIR and supply chains.
Advertisement
Advertisement
Related to this article
Informa's invitation-only Leadership Summit returns to CPHI Milan Oct. 6 as executives weigh sourcing, medicine security and reshoring pressure.
Go behind the scenes of LogiPharma USA 2026 with program director Charleen Ring and McKesson's Chris Van Norman in this Pharma Pulse special.
As HRSA's 340B Rebate Model Pilot moves toward its effective date, Valerie Bandy, PharmD, of Tecsys explains what drug-by-drug rebate tracking really demands from hospital and health system pharmacies.
In the final installment of his interview with Pharmaceutical Commerce, Cencora's Ameer Ali outlines how supply chain stakeholders should prepare systems, processes and trading partners for the shift to NDC-12.
In the final installment of his interview with Pharmaceutical Commerce, Cencora's Gregg Gorniak looks back at DSCSA's five-year evolution and where serialized data is creating value beyond compliance.
HDA's Kala Shankle unpacks the biggest open question on preemption and offers a two-step playbook for wholesalers and 3PLs preparing for national licensure.
Cardinal Health's Liberty Dewey outlines the four parallel work streams driving the NDC-12 transition, and why the biggest risk sits in trading partner handoffs rather than any single system.
Advertisement
Advertisement